[SCORE2 - an updated model for cardiovascular risk prediction].

SCORE2 – ett uppdaterat verktyg för att skatta kardiovaskulär risk.

Journal

Lakartidningen
ISSN: 1652-7518
Titre abrégé: Lakartidningen
Pays: Sweden
ID NLM: 0027707

Informations de publication

Date de publication:
29 09 2021
Historique:
entrez: 30 9 2021
pubmed: 1 10 2021
medline: 5 10 2021
Statut: epublish

Résumé

Cardiovascular disease is the most important cause of death and life-years lost in Sweden today. Cardiovascular risk prediction is a cornerstone in primary prevention; the use of antihypertensive and lipid-lowering therapy is guided by absolute cardiovascular risk. The Systematic COronary Risk Evaluation (SCORE) model has been the most widely applied model in Sweden for almost two decades. Recently, an updated model called SCORE2 was published. The new risk prediction model is based on contemporary data, predicts the risk of incident cardiovascular disease in addition to cardiovascular mortality, and accounts for competing risks, thus overcoming some major limitations with SCORE. Sweden is classified as a moderate-risk country according to the new model; here we report the risk chart for moderate-risk countries translated into Swedish.

Identifiants

pubmed: 34590704
pii: 21164
pii:

Substances chimiques

Antihypertensive Agents 0

Types de publication

Journal Article

Langues

swe

Sous-ensembles de citation

IM

Auteurs

Mattias Brunström (M)

med dr, ST-läkare, Hjärtcentrum, Norrlands universitetssjukhus, Umeå.

Jonas Andersson (J)

med dr, överläkare, medicinkliniken, Skellefteå lasarett.

Mats Eliasson (M)

professor, överläkare, medicinkliniken, Sunderby sjukhus, Luleå.

Michael Fu (M)

professor, överläkare, VO medicin, geriatrik och akutmottagning Östra, Sahlgrenska universitetssjukhuset, Göteborg.

Per-Olof Hansson (PO)

docent, chefläkare, Sahlgrenska universitetssjukhuset, Göteborg.

Stefan Söderberg (S)

professor, överläkare, Hjärtcentrum, Norrlands universitetssjukhus, Umeå.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH